Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 353

1.

Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13).

Kunikane H, Yokota I, Katakami N, Takeda K, Takayama K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, Ohashi Y, Eguchi K.

Oncol Lett. 2019 Jan;17(1):1320-1326. doi: 10.3892/ol.2018.9680. Epub 2018 Nov 9.

PMID:
30655901
2.

Salvage Pulmonary Operations Following Stereotactic Body Radiotherapy for Small Primary and Metastatic Lung Tumors: Evaluation of the Operative Procedures.

Hamakawa H, Takahashi Y, Sakanoue I, Saito T, Date N, Tomii K, Katakami N, Imagunbai T, Kokubo M.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818807431. doi: 10.1177/1533033818807431.

3.

Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S; HANSHIN Oncology Group.

Oncotarget. 2018 Oct 5;9(78):34765-34771. doi: 10.18632/oncotarget.26192. eCollection 2018 Oct 5.

4.

Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L.

Takahara M, Katakami N, Shiraiwa T, Abe K, Ayame H, Ishimaru Y, Iwamoto M, Shimizu M, Tomonaga O, Yokoyama H, Matsuoka TA, Shimomura I.

Acta Diabetol. 2018 Oct 23. doi: 10.1007/s00592-018-1244-6. [Epub ahead of print]

PMID:
30353354
5.

Different daily glycemic profiles after switching from once-daily alogliptin plus twice-daily metformin to their once-daily fixed-dose combination in Japanese type 2 diabetic patients.

Takahara M, Shiraiwa T, Katakami N, Maeno Y, Yamamoto K, Shiraiwa Y, Yoshida Y, Matsuoka TA, Shimomura I.

Endocr J. 2018 Oct 11. doi: 10.1507/endocrj.EJ18-0313. [Epub ahead of print]

6.

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).

Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata A, Katakami N, Yokota S.

BMC Cancer. 2018 Oct 3;18(1):946. doi: 10.1186/s12885-018-4819-2.

7.

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.

Masago K, Imamichi F, Masuda Y, Ariga N, Fujitomi K, Fukumine Y, Hatakenaka K, Fujita S, Katakami N.

Asia Pac J Oncol Nurs. 2018 Oct-Dec;5(4):430-434. doi: 10.4103/apjon.apjon_33_18.

8.

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.

Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S.

Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.

PMID:
30268482
9.
10.

Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study.

Akamatsu H, Koh Y, Ozawa Y, Fujimoto D, Hata A, Katakami N, Tomii K, Shimokawa T, Yamamoto N.

Clin Lung Cancer. 2018 Nov;19(6):e871-e874. doi: 10.1016/j.cllc.2018.08.001. Epub 2018 Aug 22.

11.

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S, The Hanshin Oncology Group F.

Cancer. 2018 Oct 1;124(19):3830-3838. doi: 10.1002/cncr.31678. Epub 2018 Sep 7.

PMID:
30192383
12.

Skin autofluorescence is associated with vascular complications in patients with type 2 diabetes.

Osawa S, Katakami N, Sato I, Ninomiya H, Omori K, Yamamoto Y, Takahara M, Miyashita K, Sakamoto F, Kawamori D, Matsuoka T, Shimomura I.

J Diabetes Complications. 2018 Sep;32(9):839-844. doi: 10.1016/j.jdiacomp.2018.06.009. Epub 2018 Jun 22.

PMID:
30099985
13.

Notch3-dependent ╬▓-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.

Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, Wang W, Takeuchi S, Fukuda K, Katakami N, Tomii K, Ogushi F, Nishioka Y, Talabere T, Misra S, Duan W, Fadda P, Rahman MA, Nana-Sinkam P, Evans J, Amann J, Tchekneva EE, Dikov MM, Carbone DP.

Nat Commun. 2018 Aug 10;9(1):3198. doi: 10.1038/s41467-018-05626-2.

14.

Identification of Metabolites Associated with Onset of CAD in Diabetic Patients Using CE-MS Analysis: A Pilot Study.

Omori K, Katakami N, Yamamoto Y, Ninomiya H, Takahara M, Matsuoka TA, Bamba T, Fukusaki E, Shimomura I.

J Atheroscler Thromb. 2018 Aug 1. doi: 10.5551/jat.42945. [Epub ahead of print]

15.

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK.

J Clin Oncol. 2018 Sep 10;36(26):2702-2709. doi: 10.1200/JCO.2018.77.9363. Epub 2018 Jul 30.

PMID:
30059262
16.

An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug Monitoring.

Irie K, Okada A, Yamasaki Y, Kokan C, Hata A, Kaji R, Fukushima K, Sugioka N, Okada Y, Katakami N, Fukushima S.

Ther Drug Monit. 2018 Dec;40(6):716-724. doi: 10.1097/FTD.0000000000000558.

PMID:
30048380
17.

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab.

Hata A, Katakami N.

Oncotarget. 2018 Jun 19;9(47):28292-28293. doi: 10.18632/oncotarget.25623. eCollection 2018 Jun 19. No abstract available.

18.

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.

Hata A, Harada D, Okuda C, Kaji R, Masuda Y, Takechi Y, Kozuki T, Nogami N, Katakami N.

Oncotarget. 2018 Jun 12;9(45):27789-27796. doi: 10.18632/oncotarget.25578. eCollection 2018 Jun 12.

19.

Association between Subclinical Atherosclerosis Markers and the Level of Accumulated Advanced Glycation End-Products in the Skin of Patients with Diabetes.

Ninomiya H, Katakami N, Sato I, Osawa S, Yamamoto Y, Takahara M, Kawamori D, Matsuoka TA, Shimomura I.

J Atheroscler Thromb. 2018 Dec 1;25(12):1274-1284. doi: 10.5551/jat.44859. Epub 2018 Jun 30.

20.

Randomized phase 3 and extension studies: Efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer.

Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, Arai M, Tada Y, Narabayashi M, Boku N.

Ann Oncol. 2018 Apr 18. doi: 10.1093/annonc/mdy118. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center